Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alendronic acid/guanidine dextran conjugate - DexTech Medical AB

Drug Profile

Alendronic acid/guanidine dextran conjugate - DexTech Medical AB

Alternative Names: Alendronate/dextran/guanidine; Osteodex

Latest Information Update: 16 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DexTech Medical
  • Class Antihypercalcaemics; Antineoplastics; Antithrombotics; Bisphosphonates; Calcium regulators; Drug conjugates; Glucans; Plasma expanders; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bone metastases
  • Phase I/II Multiple myeloma

Most Recent Events

  • 10 Aug 2022 Phase-I/II clinical trials in Multiple myeloma (In adults, In the elderly, Refractory metastatic disease) in Sweden (IV) (EudraCT2022-001635-91)
  • 29 Jun 2016 Discontinued - Phase-II for Bone metastases (In the elderly, Metastatic disease, In adults) in Denmark (IV) (NCT02825628)
  • 01 May 2016 DexTech Medical initiates a phase II trial for Bone metastases (In adults, In the elderly, Metastatic disease) in Sweden (IV) (NCT02825628)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top